Serum concentrations of chemerin is increased in metabolic syndromes and corresponds well with components of metabolic syndrome phenotypes: obesity, adverse lipid profile, increased blood pressure, diabetes and prediabetes, and hepatic steatosis [1,7,8,9,10]. Here, RARRES2 is linked to metabolic syndrome.